2021 |
07/19 | 851 | 853 | 837 | 846 | -0.7% | 510,200 | 551億2760万 | -5.16% |
07/16 | 859 | 865 | 852 | 852 | -1.05% | 288,700 | 555億1857万 | -4.8% |
07/15 | 864 | 870 | 854 | 861 | -0.46% | 410,800 | 561億504万 | -4.33% |
07/14 | 857 | 865 | 856 | 865 | +0.58% | 416,400 | 563億6569万 | -4.31% |
07/13 | 862 | 864 | 856 | 860 | -0.23% | 370,100 | 560億3988万 | -5.18% |
07/12 | 858 | 864 | 853 | 862 | +0.47% | 563,100 | 561億7020万 | -5.27% |
07/09 | 848 | 860 | 841 | 858 | +0.82% | 495,300 | 559億955万 | -5.82% |
07/08 | 866 | 868 | 851 | 851 | -1.73% | 461,300 | 554億5341万 | -6.89% |
07/07 | 885 | 886 | 865 | 866 | -3.02% | 664,700 | 564億3085万 | -5.36% |
07/06 | 890 | 893 | 878 | 893 | -0.45% | 348,200 | 581億9024万 | -2.3% |
07/05 | 15:00 米国Sagent社によるCOVID-19治療に対するカモスタットメシル酸塩の臨床試験(CAMELOT臨床試験)完了のお知らせ |
07/05 | 907 | 907 | 896 | 897 | -0.88% | 208,900 | 584億5089万 | -1.64% |
07/02 | 911 | 915 | 902 | 905 | -0.11% | 212,400 | 589億7220万 | -0.77% |
07/01 | 899 | 906 | 891 | 906 | +1.8% | 211,000 | 590億3736万 | -0.44% |
06/30 | 907 | 910 | 890 | 890 | -2.2% | 421,000 | 579億9476万 | -1.98% |
06/29 | 911 | 917 | 903 | 910 | -0.76% | 236,700 | 592億9801万 | +0.33% |
06/28 | 922 | 924 | 913 | 917 | +0.55% | 147,700 | 597億5415万 | +1.21% |
06/25 | 909 | 914 | 905 | 912 | +0.55% | 259,700 | 594億2833万 | +0.66% |
06/24 | 906 | 918 | 904 | 907 | -0.55% | 202,200 | 591億252万 | +0.22% |
06/23 | 915 | 919 | 908 | 912 | -0.22% | 170,600 | 594億2833万 | +0.66% |
06/22 | 914 | 919 | 908 | 914 | +1.22% | 329,300 | 595億5866万 | +0.99% |
06/21 | 906 | 924 | 900 | 903 | -1.2% | 473,100 | 588億4187万 | -0.22% |
06/18 | 15:00 人事異動について |
06/18 | 932 | 934 | 914 | 914 | -1.19% | 354,800 | 595億5866万 | +0.99% |
06/17 | 15:00 Laboratorio Elea Phoenix S.A.とのインフリキシマブバイオシミラーのアルゼンチン導出契約締結およびアルゼンチン当局への承認申請のお知らせ |
06/17 | 928 | 940 | 923 | 925 | -0.22% | 308,700 | 602億7545万 | +2.1% |
06/16 | 931 | 932 | 923 | 927 | -1.8% | 463,000 | 604億577万 | +2.32% |
06/15 | 939 | 947 | 932 | 944 | +0.96% | 247,600 | 615億1354万 | +4.08% |
06/14 | 941 | 941 | 928 | 935 | -2.71% | 468,700 | 609億2707万 | +2.97% |
06/11 | 963 | 964 | 950 | 961 | 0% | 473,200 | 626億2130万 | +5.72% |
06/10 | 945 | 966 | 934 | 961 | +0.73% | 642,700 | 626億2130万 | +5.72% |
06/09 | 948 | 979 | 942 | 954 | +2.25% | 1,548,200 | 621億6517万 | +5.07% |
06/08 | 906 | 937 | 905 | 933 | +4.71% | 1,105,500 | 607億9675万 | +2.98% |
06/07 | 909 | 919 | 891 | 891 | -2.3% | 1,059,800 | 580億5992万 | -1.66% |
06/04 | 878 | 926 | 865 | 912 | +4.23% | 2,076,000 | 594億2833万 | +0.55% |
06/03 | 852 | 879 | 852 | 875 | +2.7% | 474,100 | 570億1732万 | -3.63% |
06/02 | 852 | 857 | 842 | 852 | -0.35% | 626,900 | 555億1857万 | -6.48% |
06/01 | 872 | 875 | 855 | 855 | -2.06% | 522,600 | 557億1406万 | -6.56% |
05/31 | 868 | 883 | 867 | 873 | +0.58% | 487,300 | 568億8699万 | -5.01% |
05/28 | 852 | 868 | 851 | 868 | +1.88% | 606,100 | 565億6118万 | -5.75% |
05/27 | 863 | 868 | 852 | 852 | -2.52% | 847,300 | 555億1857万 | -7.79% |
05/26 | 880 | 880 | 865 | 874 | -1.35% | 697,300 | 569億5215万 | -5.92% |
05/25 | 899 | 903 | 886 | 886 | -1.77% | 713,900 | 577億3410万 | -4.94% |
05/24 | 906 | 911 | 894 | 902 | -0.44% | 592,500 | 587億7671万 | -3.53% |
05/21 | 906 | 913 | 903 | 906 | -0.55% | 291,400 | 590億3736万 | -3.41% |
05/20 | 904 | 911 | 899 | 911 | +0.55% | 323,000 | 593億6317万 | -3.09% |
05/19 | 904 | 911 | 900 | 906 | -0.33% | 480,800 | 590億3736万 | -3.82% |
05/18 | 918 | 918 | 897 | 909 | -0.22% | 732,000 | 592億3285万 | -3.61% |
05/17 | 927 | 948 | 906 | 911 | -1.94% | 814,200 | 593億6317万 | -3.6% |
05/14 | 15:00 定款一部変更に関するお知らせ |
05/14 | 15:00 剰余金の配当に関するお知らせ |
05/14 | 15:00 2021年3月期決算短信〔IFRS〕(連結) |
05/14 | 15:00 2021年2月製造販売承認取得品目の薬価基準収載見送りのお知らせ |
05/14 | 939 | 944 | 929 | 929 | 0% | 271,400 | 605億3610万 | -1.9% |
05/13 | 15:00 割安購入益、減損損失、棚卸資産評価損の計上及び繰延税金資産の取り崩し並びに2021年3月期通期業績予想の修正に関するお知らせ |
05/13 | 945 | 953 | 928 | 929 | -1.69% | 346,500 | 605億3610万 | -2.21% |
05/12 | 954 | 962 | 937 | 945 | -1.66% | 433,500 | 615億7870万 | -0.74% |
05/11 | 968 | 976 | 956 | 961 | -1.23% | 370,500 | 626億2130万 | +0.73% |
05/10 | 952 | 977 | 952 | 973 | +2.21% | 380,500 | 634億326万 | +1.78% |
05/07 | 946 | 955 | 938 | 952 | +2.15% | 388,200 | 620億3484万 | -0.52% |
05/06 | 930 | 944 | 929 | 932 | +1.53% | 558,800 | 607億3159万 | -2.92% |
04/30 | 918 | 929 | 916 | 918 | -0.33% | 396,400 | 598億1931万 | -4.77% |
04/28 | 15:00 カペシタビン錠300mg「日医工」 ラパチニブトシル酸塩水和物又はオキサリプラチンと併用する場合、並びにE法の用法及び用量追加のお知らせ |
04/28 | 15:00 持分法適用会社の異動(株式譲渡)および譲渡益発生に関するお知らせ |
04/28 | 925 | 927 | 916 | 921 | -1.07% | 616,300 | 600億1480万 | -4.95% |
04/27 | 938 | 940 | 925 | 931 | -0.43% | 386,700 | 606億6642万 | -4.22% |
04/26 | 937 | 941 | 928 | 935 | -0.95% | 344,200 | 609億2707万 | -4.2% |
04/23 | 938 | 954 | 938 | 944 | -0.63% | 279,600 | 615億1354万 | -3.87% |
04/22 | 15:00 (開示事項の経過)当社富山第一工場の製品における一部供給遅延に関するお知らせ |
04/22 | 940 | 950 | 937 | 950 | +0.53% | 392,600 | 619億451万 | -3.65% |
04/21 | 929 | 945 | 926 | 945 | +0.53% | 717,000 | 615億7870万 | -4.45% |
04/20 | 15:00 「ミルリーラ注射液10mg」の製造販売承認の承継および販売移管に関するお知らせ |
04/20 | 946 | 949 | 937 | 940 | -0.84% | 444,200 | 612億5289万 | -5.34% |
04/19 | 960 | 962 | 947 | 948 | -1.76% | 399,700 | 617億7419万 | -4.82% |
04/16 | 972 | 972 | 950 | 965 | +0.42% | 336,200 | 628億8195万 | -3.31% |
04/15 | 961 | 972 | 958 | 961 | +0.1% | 315,500 | 626億2130万 | -3.71% |
04/14 | 973 | 973 | 954 | 960 | -0.31% | 379,900 | 625億5614万 | -3.71% |
04/13 | 17:00 人事異動について |
04/13 | 968 | 976 | 963 | 963 | 0% | 379,000 | 627億5163万 | -3.41% |
04/12 | 947 | 967 | 947 | 963 | +1.37% | 398,200 | 627億5163万 | -3.51% |
04/09 | 939 | 956 | 939 | 950 | +1.93% | 526,600 | 619億451万 | -4.81% |
04/08 | 959 | 959 | 931 | 932 | -3.32% | 1,031,700 | 607億3159万 | -6.52% |
04/07 | 969 | 973 | 956 | 964 | -0.62% | 614,700 | 628億1679万 | -3.31% |
04/06 | 10:30 (開示事項の経過)当社の医薬品製造販売業及び当社富山第一工場での医薬品製造業における業務再開のお知らせ |
04/06 | 992 | 1,000 | 969 | 970 | -1.92% | 725,000 | 632億777万 | -2.61% |
04/05 | 1,006 | 1,007 | 986 | 989 | -0.5% | 481,900 | 644億4586万 | -0.6% |
04/02 | 999 | 1,001 | 989 | 994 | +0.1% | 411,400 | 647億7167万 | +0.1% |
04/01 | 1,000 | 1,004 | 987 | 993 | -0.2% | 375,100 | 647億651万 | +0.1% |
03/31 | 1,008 | 1,012 | 995 | 995 | -1.97% | 536,600 | 648億3683万 | +0.2% |
03/30 | 1,027 | 1,031 | 1,009 | 1,015 | -1.17% | 300,800 | 661億4009万 | +1.81% |
03/29 | 1,035 | 1,039 | 1,016 | 1,027 | -1.06% | 697,500 | 669億2204万 | +2.6% |
03/26 | 1,040 | 1,050 | 1,034 | 1,038 | +0.78% | 429,300 | 676億3883万 | +3.49% |
03/25 | 1,002 | 1,040 | 1,002 | 1,030 | +2.59% | 563,200 | 671億1753万 | +2.59% |
03/24 | 1,018 | 1,025 | 997 | 1,004 | -3% | 781,400 | 654億2330万 | -0.1% |
03/23 | 1,067 | 1,070 | 1,031 | 1,035 | -2.91% | 605,100 | 674億4334万 | +2.88% |
03/22 | 1,054 | 1,072 | 1,047 | 1,066 | +1.33% | 655,700 | 694億6338万 | +5.96% |
03/19 | 1,038 | 1,058 | 1,031 | 1,052 | +1.45% | 679,800 | 685億5110万 | +4.78% |
03/18 | 1,042 | 1,061 | 1,023 | 1,037 | -0.19% | 993,500 | 675億7367万 | +3.29% |
03/17 | 1,021 | 1,043 | 1,019 | 1,039 | +1.96% | 672,400 | 677億399万 | +3.38% |
03/16 | 990 | 1,020 | 983 | 1,019 | +2.83% | 986,500 | 664億74万 | +1.19% |
03/15 | 963 | 992 | 960 | 991 | +3.66% | 855,500 | 645億7618万 | -1.59% |
03/12 | 950 | 957 | 941 | 956 | +0.31% | 640,300 | 622億9549万 | -5.25% |
03/11 | 944 | 968 | 938 | 953 | +0.11% | 1,271,500 | 621億 | -5.83% |
03/10 | 998 | 1,005 | 929 | 952 | -4.23% | 3,177,400 | 620億3484万 | -6.11% |
03/09 | 967 | 997 | 958 | 994 | +4.19% | 1,280,600 | 647億7167万 | -2.17% |
03/08 | 947 | 967 | 938 | 954 | +1.71% | 1,146,400 | 621億6517万 | -6.19% |
03/05 | 929 | 938 | 914 | 938 | +1.3% | 1,219,000 | 611億2256万 | -8.04% |
03/04 | 900 | 930 | 899 | 926 | -0.11% | 2,724,800 | 603億4061万 | -9.48% |
03/03 | 15:00 当社に対する行政処分について |
03/03 | 921 | 932 | 902 | 927 | -1.7% | 2,612,300 | 604億577万 | -9.65% |
03/02 | 960 | 965 | 931 | 943 | -1.46% | 976,600 | 614億4838万 | -8.36% |
03/01 | 17:00 組織変更および人事異動について |
03/01 | 930 | 960 | 924 | 957 | +0.1% | 1,810,700 | 623億6065万 | -7.18% |
02/26 | 946 | 984 | 943 | 956 | -7.18% | 3,631,400 | 622億9549万 | -7.36% |
02/25 | 10:25 本日の一部報道について |
02/25 | 1,090 | 1,091 | 1,024 | 1,030 | -5.59% | 1,723,100 | 671億1753万 | -0.29% |
02/24 | 1,129 | 1,138 | 1,086 | 1,091 | -1.36% | 783,100 | 710億9245万 | +5.72% |